AstraZeneca to present data at ESC Congress 2019 that potentially redefine the treatment of heart failure

Click here to view online. Add this email to your safelist.

29 August 2019

AstraZeneca will present results from the Farxiga (dapagliflozin) Phase III DAPA-HF trial at the ESC Congress in Paris, making Farxiga the first medicine in its class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with heart failure.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.